Trials / Completed
CompletedNCT02696902
Effort to Prevent Nosocomial Pneumonia Caused by Pseudomonas Aeruginosa in Mechanically Ventilated Subjects
A Phase 2 Proof-of-concept Study to Evaluate the Efficacy and Safety of MEDI3902 in Mechanically Ventilated Patients for the Prevention of Nosocomial Pneumonia Caused by Pseudomonas Aeruginosa
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 188 (actual)
- Sponsor
- MedImmune LLC · Industry
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
Clinical trial looking to evaluate the efficacy and safety of MEDI3902 in mechanically ventilated participants for the prevention of nosocomial pneumonia caused by Pseudomonas aeruginosa.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MEDI3902 | Participants will receive a single IV dose of MEDI3902 500 mg and 1500 mg in MEDI3902 500 mg arm and MEDI3902 1500 mg arm, respectively. |
| OTHER | Placebo | Participants will receive a single IV dose of placebo matched to MEDI3902. |
Timeline
- Start date
- 2016-03-25
- Primary completion
- 2019-12-04
- Completion
- 2019-12-04
- First posted
- 2016-03-02
- Last updated
- 2021-02-04
- Results posted
- 2020-12-23
Locations
78 sites across 14 countries: United States, Austria, Belgium, Croatia, Czechia, France, Greece, Hungary, Ireland, Israel, Portugal, Spain, Turkey (Türkiye), United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02696902. Inclusion in this directory is not an endorsement.